Beta-3 Receptor Agonists | Zendy

Erasmus Bachus | Zendy; Piotr Ponikowski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Beta-3 Receptor Agonists

Author(s) -

Erasmus Bachus,

Piotr Ponikowski

Publication year - 2019

Publication title -

international cardiovascular forum journal

Language(s) - English

Resource type - Journals

eISSN - 2410-2636

pISSN - 2409-3424

DOI - 10.17987/icfj.v18i0.615

Subject(s) - mirabegron , inotrope , receptor , medicine , endocrinology , heart failure , adrenergic receptor , adrenergic , adipose tissue , beta 3 adrenergic receptor , beta (programming language) , overactive bladder , pharmacology , cardiology , pathology , alternative medicine , computer science , programming language

Beta-3 adrenergic receptors (β3-AR) have a more widespread tissue distribution in the human body as compared to beta1- and beta2 (β1/2)-adrenergic receptors, including in the bladder, brain, adipose tissue and cardiovascular system. Thus, β3- AR are potential drug targets for a wide range of therapeutic areas, both cardiovascular and non-cardiovascular including overactive bladder (OAB), depression, metabolic syndrome, obesity and heart failure (HF). β3-AR agonists that are selective to the β3-AR include CL 316,243, amibegron (SR58611A), mirabegron (YM-178) and vibegron (RVT-901). However, in HF, study results regarding a possible inotropic effect of β3-AR agonists remain equivocal and some authors report a negative inotropic effect in HF and β3-AR antagonists are also under study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research